Carmot Therapeutics Inc. (CRMO)

Carmot Therapeutics was planning to go public, but the IPO was withdrawn on Dec 11, 2023.

Stock Price: Pending

IPO price not available yet

Carmot Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Selling, General & Admin	-	6.28	4.5
Research & Development	-	37.15	20.09
Operating Expenses	-	43.43	24.59
Operating Income	-67.18	-43.43	-24.59
Interest Expense / Income	5.81	-1.43	-1.74
Other Expense / Income	-20.87	-1.5	-49.99
Pretax Income	-52.13	-40.5	27.13
Income Tax	-0.44	-1.66	1.76
Net Income	-51.69	-38.83	25.37
Free Cash Flow	-57.47	-39.45	-24.66
Effective Tax Rate	-	-	6.48%
EBITDA	-45.67	-41.29	25.9
Depreciation & Amortization	0.65	0.64	0.51
EBIT	-46.32	-41.93	25.4

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).